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Abstract
Parkinson’s Disease (PD) is the second most common neurodegenerative disorder in the
world after Alzheimer’s. The hallmark symptoms of PD are tremor and rigidity, which are caused
by the death of dopaminergic neurons, specifically within the substantia nigra of the basal ganglia.
These symptoms are often treated by Levodopa (L-DOPA), MAO-B inhibitors, and other
pharmaceuticals with the goal of increasing the dopamine concentration in the brain. To better
understand how L-DOPA impacts the brain’s dopamine dynamics, various computational models
have been developed. One model, by Véronneau-Veilleux et al. (Chaos 30, 093146, 2020),
integrates L-DOPA pharmacokinetics, dopamine dynamics, and a neurocomputational model of
the basal ganglia to predict the impact of L-DOPA regimens on a patient's motor function. In this
study, we extended the model to investigate an adjunct therapy of L-DOPA with the MAO-B
inhibitor Rasagiline utilizing an enzyme inhibition model, which showed a 1.67% increase of
dopamine concentration in the brain when compared to L-DOPA therapy alone. Our model
provides a foundation for optimizing treatment strategies using both L-DOPA and an adjunct.
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I.

Introduction
Neurodegenerative disorders occur when specific populations of neurons are progressively

lost. They are distinguished from one another by where the neurodegeneration occurs, the
symptoms that manifest, and their distinct molecular biomarkers.1 Parkinson’s disease (PD) is the
second most common neurodegenerative disorder in the world after Alzheimer’s, as approximately
10 million people are currently living with the disease,2 up from 6.1 million people in 2015.3 The
increasing incidence rate is most likely a result of the aging of the global population, although
other factors such as industrialization and exposure to pesticides may also contribute to this
increase.4
Since there is currently no known cure, research regarding PD either focuses on
understanding how it arises or developing and optimizing treatment strategies. While experimental
research undoubtedly provides crucial insight into the mechanisms that drive PD and the efficacy
of potential treatments, computational modeling can also be utilized to holistically understand PD.
There are numerous computational models that have allowed researchers to better understand the
effects of various treatments, such as deep brain stimulation (DBS) and the pharmaceutical
Levodopa (L-DOPA).5–7 However, there remains a lack of research regarding the modeling of
adjunct therapies for PD.
Therefore, this thesis integrates the pharmacokinetics of the MAO-B inhibitor Rasagiline
into Vérroneau-Veilleux et al.’s computational model of L-DOPA to study the effects of a LDOPA/Rasagiline regimen on the concentration of dopamine in a PD patient’s brain. Once the
pharmacokinetic model of Rasagiline was developed using the available data, it was initially
integrated directly into the dopamine dynamics model, however, this heuristic model was not
representative of how MAO-B inhibitors function in the body. Therefore, an enzyme inhibition
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model was made based off the irreversible binding of MAO-B by Rasagiline and its functional
recovery in the body. Together, these models represent an important step in developing models for
L-DOPA and its adjunct therapies, as they provide a foundation upon which individual patient
models can be developed.

1.1 Parkinson’s Disease (PD)

Figure 1. Symptoms of PD. The characteristic motor symptoms of PD, such as tremor and rigidity,
are just a few of the symptoms with which individuals with PD can suffer.8

The three hallmark symptoms of PD, collectively known as parkinsonism, are
bradykinesia, tremor, and rigidity. For clinicians to diagnose PD, bradykinesia and one of the other
parkinsonian symptoms must be present in a patient. These symptoms typically present
asymmetrically, causing one side of the patient to be more affected than the other. Altogether,
parkinsonism can result in decreased balance, difficulty speaking, and a decline in mobility.9
Patients with PD can also experience numerous nonmotor symptoms alongside parkinsonism, such
as depression and anxiety (Figure 1). The debilitating and systemic nature of PD, combined with
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its increasing incidence rate, makes PD of continual research interest to clinicians, scientists, and
those impacted by the disease.

Figure 2. Global prevalence of PD. PD is largely associated with older individuals and is rare in
people younger than 50. As individuals age, their risk for PD increases. This graph, produced by the
Global Burden of Disease Study (GBD) 2016 Parkinson’s Disease Collaborators, depicts the global
prevalence of PD as a function of age.4

PD is most common in individuals over the age of 50 and increases in prevalence with age,
as individuals aged 85 to 95 are most likely to be diagnosed with the disease.4 (Figure 2)
Additionally, men are 1.5 times more likely to be diagnosed with PD than women.10 The
progression of PD varies from patient to patient. Although most diagnosed individuals tend to die
from similar causes as those without the disease,11 the symptoms they suffer from serve to decrease
their quality of life.
The symptoms of PD are primarily caused by the loss of dopaminergic neurons in the
substantia nigra, one of the nuclei that composes the basal ganglia (Figure 3),12 as dopamine is
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essential in the motor pathways of the brain. Movement is initiated by the primary motor cortex, a
subsection of the cerebral cortex that is regulated by the thalamus. To ensure proper initiation and
inhibition of movement, the thalamus is regulated by the basal ganglia via a direct and indirect
neural pathway (Figure 4).13 The direct pathway aids in the initiation of intentional movement by
decreasing inhibition of the thalamus. Conversely, the indirect pathway minimizes unwanted
movement by increasing the inhibition of the thalamus. In both pathways, dopamine plays a
supporting role to ensure proper regulation. When dopaminergic neurons are lost, the amount of
dopamine in the brain decreases, therefore leading to dysregulation of these pathways and causing
the motor symptoms of PD to arise.

Figure 3. Diagram of the basal ganglia. The basal ganglia are various nuclei that interact with one
another to compose the direct and indirect pathways that regulate the thalamus and therefore control
motor fluctuations. The substantia nigra, denoted in green, is where substantial amounts of
dopaminergic neuronal death occur in PD.14
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Figure 4. Direct and indirect pathways of the basal ganglia in normal versus Parkinsonian
brains. The direct pathway is indicated in green, and the indirect pathway is indicated in red. The
substantia nigra (SNc), striatum, global pallidus internal (GPi/SNr), global pallidus external (GPe),
subthalamic nucleus (STN), and thalamus are connected via these pathways.13

There is currently no known cure for PD, therefore the treatments available are focused on
alleviating the symptoms of PD and improving patients’ quality of life. One of the most recently
developed treatments, deep brain stimulation (DBS), is a surgical procedure where electrodes in
the brain generate electrical signals to help regulate the affected neural pathways. However, since
surgery carries significant risk and the exact mechanisms that allow DBS to be successful are
largely unknown, clinicians typically recommend DBS for patients with advanced PD.
Consequently, the most common treatment options are various pharmaceuticals that aim to
diminish the effects of the reduced levels of dopamine.
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1.2 Levodopa (L-DOPA)
Undoubtedly the most common and effective treatment for PD is the pharmaceutical
Levodopa (L-DOPA), which acts as a replacement for dopamine.15 L-DOPA was first isolated
from a bean plant in 1910 by Torquato Torquati. In the following decades, much of the work
regarding L-DOPA was focused on further characterizing its chemical structure and defining its
role as a biochemical intermediate in the brain. The L-isomer of dihydroxyphenylalanine, L-DOPA
is synthesized via the addition of a hydroxy group (-OH) to L-tyrosine by the enzyme tyrosine
hydroxylase, L-DOPA is then converted to dopamine by DOPA decarboxylase (DDC), which
replaces the carboxyl group (-COOH) of L-DOPA with an amine group (-NH2).16
Once established as an essential biochemical to produce dopamine in the brain in 1957,
researchers began exploring its role as a potential therapeutic agent. However, it was not until 1967
that L-DOPA was shown to be an effective treatment for the motor symptoms of Parkinson’s, as
George Cotzias and his colleagues developed a L-DOPA regimen that is still utilized today.17 LDOPA is utilized therapeutically because unlike dopamine, it can pass through the blood-brain
barrier. However, due to the complexity of the absorption, distribution, and conversion of L-DOPA
into usable dopamine, there are numerous barriers that can decrease its efficacy. For example, LDOPA must compete with other amino acids to be successfully transported across the intestinal
wall. Additionally, L-DOPA can be converted into dopamine by DDCs and catechol-Omethyltransferases (COMTs) before it passes the blood-brain barrier, causing a reduction in its
bioavailability.15
Regardless of these drawbacks, L-DOPA is still one of the most prescribed pharmaceuticals
to treat PD.18 Typically well tolerated by most patients,19 studies have shown that, in comparison
to the dopamine agonists, L-DOPA treatment results in a greater reduction of motor symptoms.20,21
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However, L-DOPA can be prescribed either as a monotherapy or in adjunct with other
pharmaceuticals, as patients can still experience motor fluctuations when administered L-DOPA.22
These adjunct therapies include, but are not limited to, dopamine agonists and COMT inhibitors.23
Although the prescription of different adjunct therapies varies regionally,18 clinicians can also opt
for a multi-drug therapy that includes L-DOPA and monoamine oxidase B (MAO-B) inhibitors, a
class of drugs that inhibit the function of MAO-B.24

1.3 Rasagiline: An Irreversible MAO-B Inhibitor
Monoamine oxidases (MAOs) are a subset of enzymes that aids in the oxidation of
monoamines, many of which are important neurotransmitters, such as serotonin and dopamine.25
The two isoforms, MAO-A and MAO-B, have different affinities for different substrates.26
Generally, MAO-A preferentially acts on serotonin, while MAO-B preferentially degrades
dopamine,25 but it is important to note that it is still possible for dopamine to act as a substrate for
MAO-A.27 Although it may seem as if nonspecific inhibitors can aid in increasing dopamine levels,
inhibition of MAO-A has been associated with significant negative side effects. For example,
individuals prescribed nonspecific MAO inhibitors can no longer degrade tyramine,28 an ingested
monoamine found in aged meats and cheeses, potentially causing rapid increases in blood pressure
which can lead to a hypertensive crisis. Therefore, clinicians are typically hesitant to prescribe
MAO-A or nonspecific MAO inhibitors.25
Conversely, MAO-B inhibitors are more promising, as there are currently multiple
selective MAO-B inhibitors available to treat PD. Inhibitors of MAO were first recognized for
their ability to treat mood disorders, specifically depression.29 However, it was eventually
discovered that the MAO-B inhibitor Selegiline, initially named L-deprenyl, has antiparkinsonian
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effects.30 Selegiline inhibits the function of MAO-B by covalently bonding to MAO-B’s active
site.24 Since this reaction is not transient, it is considered irreversible; the only way to recover the
function of MAO-B is for the body to synthesize new enzyme.31 This irreversible mechanism
allows Selegiline to have substantial effects after a single dose, as the half-life of MAO-B is 40
days, therefore causing a slow recovery of MAO-B function in vivo.32 However, Selegiline has
negative side effects. Alongside the typical side effects, such as nausea, vomiting, and dry mouth
reported in upwards of 5% of patients, Selegiline produces L-amphetamine as a metabolite.29
While there is a lack of evidence to suggest that Selegiline’s metabolite L-amphetamine is
neurotoxic, experimental results have suggested that L-amphetamine inhibits Selegiline’s potential
neuroprotective effects, although its neuroprotective effects are also heavily debated.33,34
Additionally, at high doses, Selegiline loses its specificity for MAO-B, and begins inhibiting
MAO-A as well.29
Selegiline was approved for use by the Food and Drug Administration in 1989, and it was
not until 2006 when another MAO-B inhibitor, Rasagiline, was approved for use (Figure 5).18
Rasagiline shares many similarities with Selegiline, such as its mechanism of action and potential
side effects. However, unlike Selegiline, Rasagiline has been shown to have neuroprotective
effects, which are unrelated to its inhibition of MAO-B.35,36 One study has also shown that
implementing Rasagiline in place of Selegiline better improved patients’ motor symptoms and
sleep.37 Additionally, the International Parkinson and Movement Society found that Rasagiline can
be utilized to treat motor fluctuations in patients who are receiving L-DOPA, while there is
insufficient evidence that Selegiline can provide the same relief.22 Furthermore, one study reported
that Rasagiline had higher prescription rates than Selegiline soon after its approval.38 These factors
are why Rasagiline was chosen to modeled in this study.
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Figure 5. Chemical structures of Selegiline and Rasagiline. Although both are MAO-B
inhibitors, Selegiline and Rasagiline have distinct chemical structures.39

II.

Model
Theory and experiment are the most well-known forms of research, but computational

modeling has quickly become an integral component of the scientific process.40 Computational
research typically utilizes the numerical analysis of differential equations to analyze problems of
varying complexity. Creating a computational model typically relies on the development of
mathematical equations, with variables in the equations representing different aspects of the
system being studied. The results of computational models not only allow researchers to
understand the implications of the theories they develop, but also allow experimentalists to
determine interesting aspects of a system that merit further observational study.41
To better understand numerous facets of PD, researchers have composed a variety of
computational models.5–7 Generally, these models can be divided into two categories: abstract
models, which greatly simplify the biological systems involved and aim to elucidate the underlying
mechanisms that drive PD, and clinically predictive models, which aid doctors in determining the
efficacy of potential treatments.42 Therefore, the goal of the model ultimately dictates how it is
designed. A clinically predictive model, developed by Vérroneau-Veilleux et al.,43 combines LDOPA pharmacokinetics, dopamine dynamics, and the neurocomputational model of the basal
ganglia to predict the effect of L-DOPA regimens on a patient’s motor skills (Figure 6). The
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pharmacokinetics model represents how the body ingests, metabolizes, and distributes L-DOPA
into the bloodstream and its passage of the blood-brain barrier, while the dopamine dynamics
model expresses how the concentration of L-DOPA in the brain impacts the overall concentration
of dopamine in the brain. Finally, the neurocomputational model calculates the number of bound
dopamine receptors in the basal ganglia based on the amount of dopamine in the brain, which is
then converted into a tapping response.

Figure 6. Overview of Vérroneau-Veilleux et al.’s model.43 The dose is the input of the
pharmacokinetic model, which outputs the concentration of dopamine within the brain. This value
is then utilized in the dopamine dynamics compartment to determine L-DOPA’s impact on
dopamine levels within the brain. Finally, the electrical activity of the basal ganglia is calculated

using the amount of bound dopamine receptors, which allows for the model to predict the
tapping frequency of a patient.

2.1 Pharmacokinetics of L-DOPA
There are various ways to model drug distribution throughout the body, and the method by
which researchers model pharmacokinetics largely depend on their goal and the behavior of the
drug.44 For L-DOPA, it has been found that compartmental analysis is a good fit for how the drug
distributes and metabolizes in the body.45 Compartmental analysis involves dividing the body into
various compartments, then mathematically modeling the transfer of the drug between the
compartments to represent how the body distributes it. If the drug is distributed throughout the
entire body quickly, a single-compartment analysis typically provides a good fit for which the drug
14

can be modeled. However, if the drug preferentially distributes to some areas of the body more
quickly than others, a multi-compartment model will allow for a more accurate representation of
how the drug is the distributed.44
Vérroneau-Veilleux et al. utilized a two-compartment model for the pharmacokinetics of
L-DOPA (Figure 7). Compartment 1 represents the blood plasma, compartment 2 represents
peripheral organs and body fluids that L-DOPA additionally interacts with, and compartment 3 is
the ‘effective compartment’ that represents the brain. It’s important to note that the dose is directly
infused into compartment 1 because this analysis is modeling an intravenous infusion, which
means L-DOPA does not have to pass any barriers to enter the blood plasma.43

Figure 7. Pharmacokinetic model of L-DOPA.43 Each compartment and the exchange between
these compartments are representative of the peripheral tissues (C2), blood plasma (C1), and the
brain (C3) and the distribution of L-DOPA to these various areas, respectively.

The change in concentration of L-DOPA is modeled by relatively simple and similar
differential equations. Compartment 1 is modeled with the equation43
𝑉!

"#!
"$

= 𝑘% (𝑡) + 𝑄&! 𝐶& − (𝑄!& + 𝐶𝐿'$($ )𝐶! ,

(2.1)
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where V1 and C1 are the volume and concentration of L-DOPA in the blood plasma, respectively.
To represent the change of L-DOPA concentration over time, the right-hand side of the equation
sums all of channels allowing L-DOPA to flow into the compartment and subtracting the channels
that flow out of the compartment. Except for the infusion rate k0(t), which represents the rate at
which L-DOPA is intravenously infused, the rest of the terms on the right-hand side include an
intercompartmental clearance rate Q, and the concentration of L-DOPA in its initial compartment.
The second term is the intercompartmental clearance from the peripheral tissues to the blood
plasma Q21 and the concentration of L-DOPA in the peripheral tissues C2, as the amount of LDOPA that can flow into the blood plasma from the peripheral tissues depends on how much LDOPA is available in the peripheral tissues. Finally, the last term represents the L-DOPA flowing
out of the blood plasma, with Q12 representing the clearance from the blood plasma to the
peripheral tissues. The term CLetot= Q13+CLe1 is the sum of the remaining clearance rate between
the blood plasma and the brain and the clearance out of the blood plasma. Again, these clearance
terms depend on the concentration of L-DOPA in the blood plasma C1, as the rate at which LDOPA leaves the blood plasma is proportional to the concentration of L-DOPA within it.
The pattern of summing the L-DOPA that flows into and subtracting the L-DOPA that
flows out of the desired compartment is repeated to model the concentration in compartment 243
𝑉&

"#"
"$

= 𝑄!& 𝐶! − 𝑄&! 𝐶& .

(2.2)

Here, V2 is the volume of the peripheral tissues, C2 is the L-DOPA concentration in the peripheral
tissues, Q12 is the intercompartmental clearance rate from the blood plasma to the peripheral
tissues, and Q21 is the intercompartmental clearance from the peripheral tissues to the blood
plasma. Finally, compartment 3 is modeled, again, in a similar manner43
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𝑉)

"##
"$

= 𝑄!) 𝐶! − 𝐶𝐿') 𝐶) ,

(2.3)

where V3 is the volume of the brain, C3 is the concentration of L-DOPA in the brain, Q13 is the
intercompartmental clearance from the blood plasma to the brain, and CLe3 is the clearance out of
the brain. Compartment 3 is also known as the ‘effective’ compartment because it will impact the
concentration of dopamine in the brain, as will be seen when the pharmacodynamics of L-DOPA
is discussed (See Section 2.3). The parameters used in these equations are from a previously
published study by Baston et al. and based on a single patient,45 except for Q13, which was
estimated (Table 1).43
Table 1. Parameters for L-DOPA pharmacokinetics.43

Parameter

Symbol

Value

Volume of Compartment 1 (Blood Plasma)

V1

12 L

Volume of Compartment 2 (Peripheral Tissues)

V2

32 L

Volume of Compartment 3 (Brain)

V3

2L

Clearance Rate from the Blood Plasma to the Peripheral

Q12

9.11 L/min

Q21

10 L/min

Clearance Rate from the Blood Plasma to the Brain

Q13

0.0021 L/min

Clearance Rate out of the Blood Plasma

CLe1

0.7979 L/min

Clearance Rate out of the Brain

CLe3

0.006 L/min

Infusion Rate

k0(t)

3.33 mg/min for 30

Tissues
Clearance Rate from the Peripheral Tissues to the Blood
Plasma

minutes, else 0
mg/min
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2.2 Pharmacokinetics of Rasagiline
The pharmacokinetic model of Rasagiline was developed using previously collected data
and a common, introductory pharmacokinetic equation. A single, 1 mg dose of Rasagiline was
considered. To utilize an introductory pharmacokinetic equation that models the plasmatic
concentration of an oral drug, it was assumed that Rasagiline follows first-order kinetics, meaning
that the elimination rate of Rasagiline is proportional to its concentration within the body.
Therefore, the plasmatic concentration of Rasagiline was modeled with44
+, .% ('

𝐶* (𝑡) = -

$

&'(∗*,
+$ 0' &-% * )

.% 0#23-

,

(2.4)

$

where F represents the bioavailability of Rasagiline, D is the given dose, CL is the clearance of
the drug, VD is the volume of distribution, ka is the absorption rate constant, and t is time in minutes.
The bioavailability, dose, and clearance were all taken from a previous study that experimentally
determined the pharmacokinetic parameters of Rasagiline.46,47 However, an extensive search of
the literature did not yield values for the volume of distribution or the absorption rate constant.
Therefore, these parameters were estimated to ensure the pharmacokinetic model was consistent
with the maximum concentration and time to maximum concentration reported.47 It is important to
note that although the volume of distribution was estimated, the value that is utilized in this model
falls within the range of values reported by various researchers (Table 2).47
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Table 2. Parameters for Rasagiline pharmacokinetics.

Parameter

Symbol

Value

Bioavailability46

F

0.35

Dose

D

1 mg

Clearance of Rasagiline47

CL

94.3 L/hour

Volume of Distribution

VD

89 L

Absorption Rate

ka

0.1/hour

Maximum Concentration47

Cmax

2.5 ng/mL

Time to Maximum Concentration47

Tmax

0.5 hr

2.3 Pharmacodynamics Model
The pharmacodynamics models how the concentration of available dopamine in the neural
synapses of the brain changes over time and determines the impact of L-DOPA on this change.
This model must consider the various processes that impact the amount of available dopamine in
the neural synapses. Initially, synthesized dopamine is released into the neural synapse by the
presynaptic neuron, which acts as a signal that can be recognized by the receptors of the
postsynaptic neuron. However, not all the dopamine released by the presynaptic neuron comes into
complex with the receptors of the postsynaptic neuron. For example, dopamine transporters
(DATs) are membrane proteins that transport dopamine from the synaptic cleft back into the
cytosol of the neurons.48 While this is meant to clear dopamine from the synaptic cleft and
terminate the signaling between two neurons, DATs can reuptake dopamine before it reaches the
dopamine receptor of the postsynaptic neuron. Dopamine can also be removed from the neural
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synapse by other processes, such as degradation by enzymes or by migration outside of the neural
synapse (Figure 8).

Figure 8. Release and reuptake of dopamine in the neural synapse. Dopamine, some of which
is synthesized from L-DOPA available in the brain, is released into the synaptic cleft by the
presynaptic neuron via vesicular export. While dopamine can reach the postsynaptic neuron, a
portion of the dopamine released into the synaptic cleft either undergoes reuptake by DATs or
removal by other processes, which are not explicitly depicted.43

The pharmacodynamics of this process are modeled with the single equation:43
"#./0 ($)
"$

= 𝑓𝐼,4 (𝑡) −

5-1%2 #./0 ($)
671 8#./0 ($)9

!

− 5 𝑘:'; 𝐶"(< (𝑡).

(2.5)

The first term, f IDA(t), describes the release of dopamine into the synaptic cleft, with f representing
the fraction of neurons alive and IDA(t) being the release of dopamine by dopaminergic neurons.
There is a direct correlation between the fraction of neurons alive and the amount of dopamine
released into the synaptic cleft because as dopamine neurons die, the amount of available dopamine
decreases. The term IDA(t) can be further broken down as43
𝐼,4 (𝑡) = 𝐼,4'="( + 𝑘) 𝐶) (𝑡),

(2.6)
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with IDAendo being the amount of endogenous dopamine released by dopaminergic neurons, and
k3C3(t) representing the amount of dopamine generated by L-DOPA, which is dependent upon
amount of L-DOPA available in the brain (C3(t)). The endogenous dopamine release is considered
constant and calculated from various parameters49
𝐼,4'="( (𝑡) =

>?=3 @3
A45 B6

,

(2.7)

where r is the density of vesicles in the presynaptic neuron, P is the probability of the vesicle being
released by the presynaptic neuron, n0 is the number of dopamine molecules released by each
vesicle, v0 is the average firing rate of dopaminergic neurons, avf is the extracellular volume
fraction, and NA is Avogadro’s number. The k3 term allows for the dopamine produced and released
from the decarboxylation of L-DOPA in the brain to be calculated, and is similarly dependent upon
numerous factors:49
𝑘) = A

?#( @3
45 C(74/./0%

.

(2.8)

Here, CL is a conversion factor for milliliters to liters and MLevodopa represents the molar mass of
L-DOPA. The parameters utilized to calculated IDAendo and k3 were adopted from reference 49 and
are listed in Table 3.
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Table 3. Parameters for IDAendo and k3.49

Parameter

Symbol

Value

Terminal Density

r

0.1 * 1015 vesicles/L

Probability of Vesicle Release

P

0.1

Number of Dopamine Molecules per Vesicle

n0

3000 molecules/vesicle

Average Firing Rate

v0

4/s

Extracellular Volume Fraction

avf

0.2

Avogadro’s Number

NA

6.02 * 1017 molecules/µmol

Conversion Factor

CL

1000 mL/L

Molar Mass of Levodopa

MLevodopa

197.1879 * 106 µg/mol

The second term in Equation 2.5 represents the reuptake of dopamine by DATs. For the
reuptake of dopamine by DATs, it is assumed that dopamine comes into complex with a DAT,
which allows for the formation of dopamine-DAT complex. Subsequently, this complex
dissociates, and dopamine is transported across the plasma membrane. While this is a simple
schematic of how DATs transport dopamine across the plasma membrane, this allows researchers
to utilize Michaelis-Menten kinetics to model this process, which has been found to be a good fit
to experimental data.50 Therefore, the second term of Equation 5 is simply the Michaelis-Menten
kinetics equation for DATs, where Vmax is the maximum rate at which dopamine associates with
DATs, Km is the Michaelis constant of the reaction, and Cdop(t) is the concentration of dopamine,
which acts as the substrate of the DATs. Again, it is assumed that there is a linear correlation
between the reuptake by DATs and the percent of neurons alive, therefore causing the MichaelisMenten equation to be multiplied by f.
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Finally, the last term in the pharmacodynamics equation (Equation 2.5) represents the
linear removal of dopamine from the synaptic cleft by other processes. The removal term includes
the concentration of dopamine (Cdop(t)) and the linear removal rate krem, which accounts for
removal due to diffusion and the metabolism of dopamine by various enzymes, such as MAO-B
and COMT. Unlike the previous terms, it is assumed that the removal of dopamine from the
synaptic cleft increases as dopaminergic neurons die. Therefore, this removal term is multiplied
!

by 5 rather than f. The parameters for the pharmacodynamics model are denoted in Table 4.
Table 4. Pharmacodynamic parameters.43

Parameter

Symbol

Value

Fraction of Neurons Alive

f

0.3

Endogenous Dopamine Release Rate

IDAendo

0.9963 µmol/L/s

Maximum Reuptake Rate by DATs

Vmax

4 µmol/L/s

Michaelis Constant for DATs

Km

0.16 µmol/L

Removal Rate

krem

0.04/s
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2.4 Modeling the Impact of Rasagiline on MAO-B
Initially, the model developed by Véronneau-Veilleux et al. was augmented by directly
incorporating the concentration of Rasagiline into the pharmacodynamics equation, which yielded
"#./0 ($)
"$

= 𝑓𝐼,4 (𝑡) −

5-1%2 #./0 ($)

!

6.1 8#./0 ($)9

D
− 5 𝑘:';
𝐶"(< (𝑡).

(2.9)

The term k’rem can be further broken down into
# ($)

D
𝑘:';
= 𝑘:'; 11 − 𝛽 # 8

81%2

4,

(2.10)

where b is the percentage of removal due to MAO-B, CR(t) is the blood plasma concentration of
Rasagiline calculated by Equation 2.4, and CRmax is the maximal concentration of Rasagiline
yielded by Equation 2.4, which is 2.71 ng/mL. The literature does not specify how much each
enzyme contributes to the overall removal due to krem, therefore it was assumed that MAO-B is the
cause of half of the dopamine removal, making b = 0.5.
Theoretically, as the concentration of Rasagiline in the bloodstream increases, its ability to
inhibit MAO-B should increase, therefore causing the removal due to MAO-B to decrease. A
function that decreases krem as CR(t) increases, such as the one provided in Equation 2.10, allows
for this relationship to be mathematically modeled. To understand how this equation accurately
models this relationship, it is best to consider when CR(t) = 0 and CR(t) = CRmax, which represents
when a patient has not taken Rasagiline and when a patient has the maximum possible
# ($)

concentration of Rasagiline in their bloodstream, respectively. When CR(t) = 0, the 𝛽 # 8

81%2

term

vanishes, and k’rem = krem, demonstrating that there is not impact on the removal of dopamine
without Rasagiline. When CR(t) = CRmax, the equation yields k’rem = 0.5krem, which means that the
removal of dopamine has been halved when the concentration of Rasagiline has been maximized.
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While this heuristic model properly reflects how Rasagiline can theoretically impact the
removal of dopamine from the neural synapse, it does not consider the mechanism through which
Rasagiline inhibits MAO-B, nor does it consider how MAO-B function is recovered in the body.
As previously discussed in Section 1.3, Rasagiline irreversibly binds MAO-B, and the only way
to regain MAO-B function is to synthesize new enzyme. To better model this relationship, an
enzyme inhibition model was developed (Figure 9).

Figure 9. Enzyme inhibition model. Schematic of the proposed augmentation (in yellow) to the LDOPA model (in purple), which assumes that Rasagiline and L-DOPA have no interactions,
therefore making their pharmacokinetics independent of one another.

For this model, a new differential equation describing the relationship between Rasagiline
and the amount of functional MAO-B was utilized. Specifically,
"C
"$

# ($)

= 𝑘EF= − 𝑘"'G 𝑀 − 𝑘H=IJ$ # 8

81%2

𝑀,

(2.11)

where M is the percent of functional MAO-B, ksyn is the synthesis rate of MAO-B, kdeg is the
degradation rate of MAO-B, and kinact is the inactivation rate of MAO-B by Rasagiline. To develop
this differential equation, several assumptions were made. First, it was assumed that the synthesis
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rate of MAO-B is constant and not dependent upon any outside factors. Conversely, it was assumed
that the degradation of MAO-B is dependent upon the concentration of functional MAO-B, as the
degradation of MAO-B can only occur when MAO-B is present. Additionally, while the value of
kinact have been reported,51 the values for ksyn and kdeg have not been experimentally determined.
However, researchers determined the half-time it takes to synthesize MAO-B in the brain, which
is 40 days.32 Therefore, ksyn and kdeg were estimated so that the model accurately replicated this
recovery time (Table 5). Since this model also focuses on the percent of functional MAO-B rather
than the overall amount of MAO-B available in the brain, ksyn and kdeg were assumed to be equal,
as this ensures the function plateaus at a value of 1.52
Table 5. Parameters for inhibition of MAO-B.

Parameter

Symbol

Value

Synthesis Rate of MAO-B

ksyn

0.1%/day

Degradation Rate of MAO-B

kdeg

0.1/day

Inactivation Rate of MAO-B by Rasagiline51

kinact

76.32/day

With this differential equation, the impact of MAO-B inhibition on the
pharmacodynamics was modeled by modifying Equation 2.5, yielding
"#./0 ($)
"$

= 𝑓𝐼,4 (𝑡) −

5-1%2 #./0 ($)
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!

!

DD
− 5 𝑘:';
𝐶"(< (𝑡) − 5 𝑘:';C4K 𝑀𝐶"(< (𝑡).

(2.12)

Here, k’’rem is the removal rate of dopamine due to other processes and kremMAO is the removal of
dopamine due to MAO-B. Again, it was assumed that half of krem is due to MAO-B, and therefore
k’’rem = kremMAO = 0.5krem. Similarly to krem, it was assumed that removal due to MAO-B increases
!

as the fraction of neurons alive decrease, and therefore the kremMAO term was multiplied by 5.
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2.5 Computational Methods
The model developed by Véronneau-Veilleux et al. was initially replicated using Python
to confirm that the L-DOPA pharmacokinetics and pharmacodynamics properly describe their
respective mechanisms. Although Véronneau-Veilleux et al. coded their model in MatLab, Python
was used in this study because it is open source, therefore making it easier to access. To solve the
system of equations provided by the model, the function solve_ivp was imported from the SciPy
library. A function, defined as ldopapk, included Equations 2.1, 2.2, 2.3, and 2.5 and was generated
so that it could be input into solve_ivp. Using the Runge-Kutta method of order 5, the solve_ivp
function calculated solutions for the L-DOPA pharmacokinetics and pharmacodynamic equations
over a timespan of 300 minutes. These solutions were then plotted versus time to compare the
results of the replication to the published results of the original model.
The pharmacokinetics of Rasagiline were calculated separately from the L-DOPA
pharmacokinetics and pharmacodynamics. The heuristic model (Equations 2.9 and 2.10) was
included in the ldopapk so that they were solved alongside Equations 2.1, 2.2, 2.3, and 2.5. Again,
these differential equations were solved over a 300-minute timespan. To analyze the difference
between the original model and the heuristic model, the percent difference in dopamine was
calculated and then averaged.
To incorporate the enzyme inhibition model, a new function MAOB was defined to solve
Equation 2.11 with the solve_ivp function. Due to the timescale over which MAO-B function is
physiologically recovered, this equation was solved on a timescale of days rather than minutes.
The numerical data was interpolated using the interpolate.interp1d function of the SciPy library
before inserting the values of M into Equation 2.12. The enzyme inhibition model was solved over
a timespan of 11 days. During this simulation, Rasagiline was only administered on the first day,
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while L-DOPA was administered once daily. To monitor the effects of a L-DOPA/Rasagiline
adjunct therapy compared to L-DOPA alone, the percent change in dopamine between these two
models was calculated, graphed, and averaged. To review the entire code of the model, see the
Appendix.

III.

Results
The model successfully replicated the pharmacokinetics produced by Véronneau-Veilleux

et al., as can be seen in Figure 10 and 11. Our model returns a curve with similar shapes and values
as the ones published by Véronneau-Veilleux et al., indicating we successfully replicated the
pharmacokinetics model. Unfortunately, Véronneau-Veilleux et al. did not publish a graph of the
peripheral concentration of L-DOPA (C2), and therefore we could not compare our results.

(b)

Figure 10. L-DOPA blood plasma concentrations generated by (a) Véronneau-Veilleux et al.
and (b) our replication.
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(a)

(b)

Figure 11. L-DOPA brain concentrations generated by (a) Véronneau-Veilleux et al. and (b)
our replication.

Although the replication of the pharmacokinetic model was successful, there were
inconsistencies between Véronneau-Veilleux et al.’s pharmacodynamics and our results.
Compared to Véronneau-Veilleux et al.’s pharmacodynamics (Figure 12a), we observed an initial
‘jump’ in our pharmacodynamic model (Figure 12b). However, both curves had a similar shape,
which indicates this ‘jump’ is potentially an artifact of the solver and not a mathematical error in
the equations. Extensive debugging did not resolve the inconsistency. The numerical solution
shows the concentration of dopamine rapidly increasing over the initial data points. Changing the
ordinary differential equation (ODE) solver method from the Runge-Kutta method of order 5 to
other methods such as the Runge-Kutta methods of orders 3 and 8, the backward differentiation
formula (BDF) method, and the Adams-BDF method did not significantly change our results.
Additionally, the time-step over which the differential equation was decreased by a factor of 100,
as reducing the time-step generally reduces the error generated by numerical methods.
Unfortunately, decreasing the time-step did not significantly improve the results.
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(a)

(b)

Figure 12. Dopamine brain concentrations generated by (a) Véronneau-Veilleux et al. and (b)
our replication.

Due to the inconsistences in the pharmacodynamics model, the replication of VéronneauVeilleux et al.’s model was not able to be further extended to include their neurocomputational
model, which characterizes the electrical activity of the basal ganglia and how it translates to a
motor response. The motor response is measured via predicted finger tapping frequency, as the
finger tapping task in a common clinical biomarker used to assess the motor function of PD
patients.53 The more a patient can tap their finger in a given time frame, the better their motor
function is, and therefore they receive a higher Unified Parkinson’s Disease Rating Scale (UPDRS)
score.

3.1 Heuristic Model
The first incorporation of Rasagiline into Véronneau-Veilleux et al.’s model with
Equations 2.9 and 2.10 yielded a slight increase in the concentration of dopamine in the brain
(Figure 13a). The percent change in dopamine is graphed in Figure 14b. The cause of the
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oscillatory behavior seen in the results remains unknown but is perhaps an artifact of the ODE
solver. On average, the heuristic model yielded a 0.8% increase in dopamine available in the brain,
which was calculated using the average function from the NumPy library. Without the
neurocomputational model, it is difficult to predict the exact effects that the 0.8% increase in brain
dopamine concentration will have on a patient’s motor function. Therefore, future work will
involve further investigating and resolving the initial ‘jump,’ as well as integrating the
neurocomputational model to better understand the impact of a L-DOPA/Rasagiline adjunct
therapy on a patient’s motor function.

(a)

(b)

Figure 13. (a) Dopamine brain concentration generated by our initial replication and heuristic
model, and (b) percent change in dopamine brain concentration for the heuristic model.

3.2 Enzyme Inhibition Model
The modeling of the percent of MAO-B inhibition by Rasagiline (Equation 2.11) versus
time is depicted in Figure 14. In this model, Rasagiline quickly inhibits the majority of functional
MAO-B within a few days and undergoes a much longer period of recovery. Utilizing the kinact
value derived from literature and estimating the values of ksyn and kdeg, this model takes
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approximately 80 days to completely recover functionality of MAO-B, which is consistent with
the 40-day half-time previously reported.32 When Rasagiline is completely excreted from the body
at approximately 25 days, there is a noticeable change it the ‘recovery slope,’ indicating that
Rasagiline is no longer inhibiting MAO-B.

Figure 14. Model of MAO-B inhibition by Rasagiline.

To understand the longitudinal behavior of the enzyme inhibition model, the simulation
was run over a timespan of 11 days, with Rasagiline being administered on the first day only and
L-DOPA being administered at the start of every day (Figure 15). While our model does not
initially cause a noticeable change in the concentration of dopamine in the brain, the effects of
Rasagiline becomes more apparent as the simulation runs, consistent with the known, long-lasting
effects of Rasagiline on MAO-B inhibition. For example, one study reported it took patients
numerous weeks to recover MAO-B function after Rasagiline therapy ended.54 When the percent
increase of dopamine concentration was graphed as a function of time (Figure 18), it was observed
that the percent change ‘spikes’ during L-DOPA administration. On average, the enzyme
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inhibition model caused a 1.67% increase in dopamine concentration. Again, it is difficult to infer
the impact this percent increase in dopamine would have on a patient’s motor function.

(a)

(b)

Figure 15. (a) Dopamine brain concentrations generated by our initial replication and the
enzyme inhibition model, and (b) percent change in dopamine brain concentrations for
enzyme inhibition model.

IV.

Conclusions
The various augmentations made to Véronneau-Veilleux et al.’s model provide crucial

insight into computationally modeling pharmaceutical therapies for the treatment of PD. The
heuristic model, which did not consider the physical mechanism by which Rasagiline inhibits
MAO-B, provides a ‘toy’ model that mathematically demonstrates the potential effects of
Rasagiline on the concentration of dopamine, while the enzyme inhibition model provides
interesting insight into the potential mechanisms through which Rasagiline treats PD symptoms.
As previously discussed in Section 1.3, Rasagiline is known to have neuroprotective effects outside
of its ability to inhibit MAO-B. Since the incorporation of Rasagiline into this model did not
increase the concentration of dopamine in the brain nearly as much as the modeled L-DOPA
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therapy alone, we hypothesize that the clinical benefits observed from taking Rasagiline are largely
due to its reported neuroprotective effects. Therefore, we suggest that future computational studies
of Rasagiline focus on modelling its potential neuroprotective effects and determining how these
effects impact a patient’s motor function.
However, with the difficulties of modeling an adjunct therapy with long-term effects, such
as Rasagiline, alongside a primary therapy with shorter-term effects, such as L-DOPA, it is
recommended that future endeavors to model adjunct therapies involve drugs that act on similar
timescales. For example, it may be easier to model the effects of dopamine agonists or COMT
inhibitors alongside L-DOPA, therefore making them better therapeutic candidates for future
modeling studies. Hopefully, the foundation created by this thesis will aid future researchers in
better understanding the effects of current pharmaceuticals used to treat PD, which in turn will
allow for the optimization of treatment strategies to manage the symptoms of PD.

V.

Appendix
Below is the Python Version 3.9 code utilized to run the heuristic and enzyme inhibition

model. This code was written and ran in two different systems, specifically in Spyder, which was
distributed through Anaconda, and Google Colab.

#!/usr/bin/env python3
# -*- coding: utf-8 -*"""
Created on Tue Oct 26 11:46:04 2021
Author: Olivia Williams
Description: This code includes a replication of the
pharmacokinetic/pharmacodynamic model published by Vérroneau-Veilleux et
al., as well as augmentations made to this model to incorporate Rasagiline
into an L-DOPA regimen. (Chaos 30, 093146, 2020) While the heuristic model
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mathematically models Rasagiline’s potential effects on the dopamine
concentration of the brain, the enzyme inhibition model considers how
Rasagiline functions within the body and determines its impact on the
amount of functional Mao-B available in the body.
"""
#!/usr/bin/env python3
# -*- coding: utf-8 -*#Heuristic and Enzyme Inhibition Model.py
from scipy.integrate import solve_ivp
from scipy.interpolate import interp1d
import numpy as np
import matplotlib.pyplot as plt
#Defining variables needed for Rasagiline pharmacokinetics
F = .35 #bioavailability
Vd = 89 #volume of distribution (L)
D = 1 #dose (mg)
CL = 94.3/60 #clearance (L/h)
k = CL/Vd #elimination constant (1/h)
ka = 6/60 #absorption constant (1/h)
CRmax= 2.701
x = np.linspace(0,300,10000)
#Solving for the concentration of Rasagiline and plotting the Results
CR = 1000*((F*D)/Vd)*((ka*(np.exp(-CL*x/Vd)-np.exp(-ka*x)))/(ka-(CL/Vd)))
#Equation 2.4
plt.figure('Rasagiline Concentration', figsize = (8, 8))
plt.cla()
plt.plot(x, CR, linewidth = 3, color = 'b')
def figset ():
ax = plt.gca()
ax.axis('tight')
ax.grid(False) #, linewidth = 1)
plt.setp(ax.spines.values(), linewidth=1.5)
ax.xaxis.set_tick_params(width=1.5)
ax.yaxis.set_tick_params(width=1.5)
plt.xticks(fontsize = 16)
plt.yticks(fontsize = 16)
return ax
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ax = figset()
ax.set_xlabel('Time (minutes)', fontsize = 20)
ax.set_ylabel('Concentration (ng/mL)', fontsize = 20)
#defining a function MAOB to solve to enzyme inhibition model
def MAOB (t, state):
M = state
F = .35
Vd = 89
D = 1
CLR = 94.3
ka = 6/60
CRmax= 2.701
t0 = 0

#define variables
#bioavailability
#volume of distribution (L)
#dose (mg)
#clearance (L/h)
#absorption constant (1/h)
#maximum concentration of Rasagiline

CR = 1000*((F*D)/Vd)*((ka*(np.exp(-CLR*t/Vd)-np.exp(-ka*t)))/(ka(CLR/Vd))) #Equation 2.4
ksyn = (0.1)
#synthesis rate of MAOB
kdeg = (0.1)
#degradation rate of MAOB
kinact = (.053*60*24)*(CR/2.71) #inactivation rate of MAOB, which is
dependent upon the concentration of Rasagiline
dMdt = ksyn - kdeg*M -kinact*(M)#Equation 2.11
return dMdt
#defining a solution to MAOB
def sol():
tspan = [0,120] #Solving Equation 2.11 over the span of 120 days
state0 = [1,0] #Initial conditions, assuming the patient has total MAOB
function
state = solve_ivp(MAOB, tspan, state0, method='RK45', t_eval = None,
dense_output=False, events=None,vectorized=False,args=None,
first_step=.5,max_step=.5) #solving Equation 2.11
return state.t, state.y[0,:]
t, M = sol()
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#interpolating the solution of Equation 2.11 so that it may be used in the
Pharmacodynamics model
x_data = t
y_data = M
y_f = interp1d(x_data, y_data, 'linear')
#defining a function to solve the L-DOPA pharmacokinetcs and
pharmacodynamics
def ldopapk (t, state):
c1, c2, c3, cdop, cdop2, cdop3 = state

#define variables

if 10 <= t < 40 or 1440 <= t <1470 or 2880<=t<2910 or 4320<=t<4350 or
5760<=t<5790 or 7200<=t<7230 or 8640<=t<8670 or 10080<=t<10110 or
11520<=t<11550 or 12960<=t<12990 or 14400<=t<14430:
k0 = 3.33
#dosing of L-DOPA for 30 minutes every day
(mg/min)
else: k0 = 0
v1 = 12
#Volume of Compartment 1 (L)
v2 = 32
#Volume of Compartment 2 (L)
v3 = 2
#Volume of Compartment 3 (L)
q12 = 9.11
#Intercompartmental Clearance between Compartment
from 1 to 2 (L/min)
q21 = 10
#Intercompartmental Clearance between Compartment
from 2 to 1 (L/min)
q13 = 0.0021
#Intercompartmental Clearance between Compartment
from 1 to 3 (L/min)
cle3 = 0.006
#Clearance from Compartment 3 (L/min)
cle1 = 0.7979
#Clearance from Compartment 1 (L/min)
cletot = cle1 + q13 #Total Clearance (L/min)
f = 0.3
#Fraction of Neurons Alive (unitless)
idaendo = 0.9963
#Indogenous Dopamine (umol/L.s)
vmax = 4
#Maximal reuptake rate by DATs (umol/L.s)
km = 0.16
#DATs dissociation constant (umol/L)
krem = 0.04
#Removal Rate (1/s)
kremaug = 0.02
P = 0.07
#Vesicular release probablity (unitless)
CL = 1000
#Conversion factor (mL/L)
v0 = 3
#Average firing rate (1/s)
avf = 0.2
#Extracellular volume fraction (unitless)
ML = 197.1879
#Molar mass of L-DOPA (ug/mol)
k3dop = (P*CL*v0)/(avf*ML)
#Removal constant
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F = .35
Vd = 89
D = 1
CLR = 94.3/60
ka = 6/60
CRmax= 2.701
t0 = 0

#bioavailability
#volume of distribution (L)
#dose (mg)
#clearance (L/h)
#absorption constant (1/h)
#maximum concentration of Rasagiline
#time Rasagiline was administered

CR = 1000*((F*D)/Vd)*((ka*(np.exp(-CLR*t/Vd)-np.exp(-ka*t)))/(ka(CLR/Vd))) #Equation 2.4
dc1dt = (k0 + q21*c2 - (q12 + cletot)*c1)/v1 #Change in L-DOPA
concentration of Compartment 1 over time (Equation 2.1)
dc2dt = (q12*c1 - q21*c2)/v2
#Change in L-DOPA
concentration of Compartment 2 (peripheral tissues) over time (Equation
2.2)
dc3dt = ((q13*c1) - (cle3*c3))/(v3*f)
#Change in L-DOPA
concentration of Compartment 3 (brain) over time (Equation 2.3)
dcdopdt = (f*(idaendo+(k3dop*c3)))-((f*vmax*cdop)/(km+cdop))((krem*(1-(0/2)*(1-(CR)/CRmax))*cdop)/f)
#Change of Dopamine
Concentration in the brain over time (Equation 2.5)
dcdop2dt = (f*(idaendo+(k3dop*c3)))-((f*vmax*cdop2)/(km+cdop2))((krem*(1-(1/2)*((CR)/CRmax))*cdop2)/f)
#Change of Dopamine
Concentration in the brain over time with heuristic model (Equation 2.9)
dcdop3dt = (f*(idaendo+(k3dop*c3)))-((f*vmax*cdop3)/(km+cdop3))((kremaug*cdop3)/f)-((kremaug*(y_f(t/1440))*cdop3)/f) #Change in Dopamine
Concentration in the brain over time with enzyme inhibition model
(Equation 2.12)
return
dc1dt, dc2dt, dc3dt, dcdopdt, dcdop2dt, dcdop3dt
#return ODEs
def sol():
tspan = [0, 15840]
#Define time span
state0 = [0, 0, 0, 0.025, 0.025, 0.025]
#Define initial
conditions
state = solve_ivp(ldopapk, tspan, state0, method='RK45', t_eval =
None, dense_output=False, events=None,vectorized=False,args=None)
#Solve ODEs (Equations 2.1, 2.2, 2.3, )
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return state.t, state.y[0,:], state.y[1,:], state.y[2,:],
state.y[3,:], state.y[4, :], state.y[5,:] #return solutions
t, c1, c2, c3, cdop, cdop2, cdop3 = sol()
#calculate average percent difference between enzyme inhibition model and
original model
deltacdop = ((cdop3-cdop)/cdop)*100
b = np.average(deltacdop)
print(b)
#graph results
plt.figure('L-DOPA Pharmacokinetics', figsize = (8, 8))
plt.cla()
plt.plot(t, c1, linewidth = 3, color = 'r')
ax = figset()
ax.set_xlabel('Time (minutes)', fontsize = 20)
ax.set_ylabel('L-DOPA Blood Plasma Concentration (ug/mL)', fontsize = 20)
plt.figure('Brain L-DOPA Concentration (ug/mL)', figsize = (8, 8))
plt.cla()
plt.plot(t, c3, linewidth = 3, color = 'r')
#plt.plot(t, cdop, linewidth = 3, color = 'b')
plt.xlim([0,300])
ax = figset()
ax.set_xlabel('Time (minutes)', fontsize = 20)
ax.set_ylabel('L-DOPA Brain Concentration (ug/mL)', fontsize = 20)
#ax.legend(['L-DOPA', 'Dopamine'], fontsize = 16, framealpha = 1, loc =
'lower center', ncol = 2)
plt.figure('Dopamine Concentration in Brain', figsize = (8, 8))
plt.cla()
plt.plot(t2, cdop, linewidth = 3, color = 'r')
#plt.plot(t2, cdopadj,linewidth = 3, color = 'g')
plt.xlim([0, 300])
plt.ylim([0.02, 0.11])
#plt.plot(t2, cdop2, linewidth = 3, color = 'b')
plt.plot(t2,cdop3, linewidth = 3, color = 'g')
ax = figset()
ax.set_xlabel('Time (days)', fontsize = 20)
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ax.set_ylabel('Concentration (umol/L)', fontsize = 20)
ax.legend(['No Rasagiline', 'With Rasagaline'], fontsize = 16, framealpha
= 1, loc = 'lower center', ncol = 2)
plt.figure('Change in Dopamine Concentration', figsize = (8, 8))
plt.cla()
plt.plot(t2, deltacdop, linewidth = 3, color = 'b')
ax = figset()
ax.set_xlabel('Time (days)', fontsize = 20)
ax.set_ylabel('Percentage Change in Dopamine Concentration', fontsize =
20)
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